Immunohistochemical analysis of tissue sections of both primary and metastatic sites showed that TG2 expression of primary site tumor samples from metastatic RCC patients was significantly higher compared to that of non-metastatic RCC patients. The gene discussed is TGM2; the disease is renal cell carcinoma.